Expansion of Precision Fluid Control Products for Medical and Semiconductor Applications
First written in FY2019. 4 of 15 entries say "Restated". Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1RestatedAnnual report
「Medical-related components remained weak because of customer inventory adjustments and delays in product launches.」
Medical-related components have continued to perform weakly because of customer inventory adjustments and delays in product launches. - 2026-08-10RestatedResults
「また医療関連部品の客先での在庫調整や製品立上げ遅れの影響を受けたことから、全体では減収減益となりました。」
医療関連部品の客先在庫調整と製品立上げ遅れが部門業績の制約として継続している。 - FY2026Production cuts in medical-related components for ChinaAnnual report
「Lower production of some medical-related components for China resulted in lower revenue and lower profit.」
While expanding medical and precision fluid-control products, the company reduced production of some medical-related components for China. - FY2026-H1Medical-related components post higher revenue, but LCD and semiconductor market impact continuesAnnual report
「Revenue from medical-related and automotive-related components increased, but the significant impact of the LCD and semiconductor markets resulted in higher revenue and lower profit.」
Revenue from medical-related components increased, but the significant impact of the LCD and semiconductor markets resulted in higher revenue and lower profit for the segment as a whole, including precision fluid-control products. - FY2025Continued product expansion, but launch delays and weakness in ChinaAnnual report
「Overall revenue increased and profit declined, due to delays in launching some new products in the medical market and the economic slowdown in the Chinese market.」
While continuing to expand development of medical and precision fluid-control products, delays in launching some new products and weakness in the Chinese market constrained segment performance. - FY2025-H1WorsenedAnnual report
「The medical market posted lower revenue as inventory adjustments and delays in product launches continued, while overall revenue increased and profit declined.」
In addition to excess distribution inventories of medical equipment, continued delays in product launches resulted in lower revenue in the medical market. - FY2024AdvancedAnnual report
「We are also focusing on and expanding the development of pressure and flow controllers, including software, for use in medical equipment. In addition, we are developing new precision cylinders centered on our core products, low-friction air cylinders using air-bearing and diaphragm mechanisms, while also working to expand our lineup of precision pressure controllers for controlling these products and to develop controllers for the precision control of the various gases and liquids used in medical and analytical equipment.」
For precision fluid-control products for medical and semiconductor applications, the company is expanding its development scope to software technologies, precision cylinders, pressure and flow controllers, and unit and equipment solutions. - FY2024-Q3Excess distribution inventories of medical equipment weigh on the medical marketAnnual report
「The medical market was affected by excess distribution inventories of medical equipment produced in larger volumes during the COVID-19 pandemic, resulting in lower revenue and lower profit.」
The company explained that, while it is expanding its medical product lineup, excess distribution inventories of medical equipment resulted in lower revenue and lower profit in the medical market. - FY2023AdvancedAnnual report
「In the medical field, we are developing components for disposable products, such as rubber valves and check valves made with specialty medical-grade silicone, as well as fluid pressure and flow controllers and products with electronic circuit boards that provide greater added value. We are also broadening our focus to include unit products and equipment that control these component devices by adding software capabilities.」
For precision fluid-control products for medical applications, the company is expanding its development scope to products with electronic circuit boards, software technologies, and unit and equipment solutions. - FY2023-Q3RestatedAnnual report
「We will work to enhance corporate value by improving margins through stronger production technologies, launching new products in the medical field, expanding our businesses and pursuing business profits, and further strengthening management.」
The company continues to pursue business expansion and operating profit growth by launching new products in the medical field. - FY2023-Q2RestatedAnnual report
「We will work to enhance corporate value by improving margins through stronger production technologies, launching new products in the medical field, expanding our businesses and pursuing business profits, and further strengthening management.」
The company continues to pursue business expansion through the launch of new products for the medical field. It also explains that the medical market remained strong. - FY2019First statedAnnual report
「The Control Equipment Division is working to expand products for precision control applications requiring precision fluid control, including the medical field and semiconductor manufacturing processes.」
This is the first description of expanding low-friction actuators, precision pressure-control equipment, fluid-control equipment, units and systems, and other products for medical applications and semiconductor manufacturing processes as an independent initiative.